NCT02122913 2026-02-05A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat CancerBayerPhase 1 Completed75 enrolled 3 FDA
NCT03212404 2025-02-03Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced CancersCheckpoint Therapeutics, Inc.Phase 1 Active not recruiting272 enrolled 1 FDA